Conexus is a personalized, minimally invasive tumor targeted immunotherapy for the treatment of most advanced solid cancer tumors. Conexus destroys the environmental condition for tumor cell growth during the inflammation stage. This ability to corrode, destroy and starve the tumor mass is due to an inflammatory response induced by coagulation or interaction with the malignant cells and extremely high concentration of the cytotoxic drugs injected locally.
Conexus is a unique tumor targeted infiltration of specific tumoric antigenic agents and specific instigating cytokine treatment that combine five FDA approved medicines and compounds with a new indication, directed towards the treatment of all stage solid cancer tumors. It is water-soluble and infused under high pressure, so the blended compound can penetrate the entire tumor and its tumor cells for up to 20 days, not one or two days as occurs in conventional therapy. This oxidant effectively coagulates the tumor mass by disturbing micro blood vessels throughout the tumor, ultimately leading to a higher concentration of injected drugs within the now coagulated tumor. This coagulation effectively changes the extracellular matrix by altering biochemical components, e.g. collagen, reticular fibers and other large molecules, which when combined bring about a soft, semisolid state tumor.
Another unique feature of Conexus is its ability to eliminate the need to use any of the current cancer treatment protocols (e.g. surgery, radiation and/or conventional chemotherapy) in exchange for a minimally invasive procedure with no side effects. Conexus offers patients significant reductions in the amount of chemo medicine required and the corresponding reduction in overall treatment costs. Moreover, by targeting deadly tumor cells only, crucial healthy cells maintain a degree functionality and typically offer the patient: